AstraZeneca today appointed Dr. Susan Galbraith to lead Oncology Research & Development from initial discovery through late-stage development. Her appointment follows the passing of José Baselga earlier this year. She will join the Company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot. Susan previously led early-stage Oncology R&D, overseeing the successful progression of seven programmes into Phase III trials, with four new medicines now approved in countries around the world. During this time, she played a pivotal role in the evolution of AstraZeneca’s Oncology strategy, supporting pioneering research, embracing cutting-edge technologies and forging successful partnerships to transform productivity and scientific output. Read more